UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancer treatments, will release its 2024 third quarter financial results on Wednesday, November 6, 2024, before market open. The company will host a conference call and live audio webcast at 10:00 AM ET on the same day. The webcast will be accessible through UroGen's Investor Relations website, with a replay available for approximately 30 days afterward.
UroGen Pharma (Nasdaq: URGN), un'azienda biotecnologica focalizzata sui trattamenti per il cancro uroteliale e speciali, pubblicherà i suoi risultati finanziari del terzo trimestre 2024 mercoledì 6 novembre 2024, prima dell'apertura del mercato. L'azienda ospiterà una conference call e un webcast audio dal vivo alle 10:00 AM ET dello stesso giorno. Il webcast sarà accessibile tramite il sito web delle Relazioni con gli Investitori di UroGen, con una registrazione disponibile per circa 30 giorni dopo.
UroGen Pharma (Nasdaq: URGN), una empresa biotecnológica centrada en tratamientos para cáncer urotelial y especializado, publicará sus resultados financieros del tercer trimestre de 2024 el miércoles 6 de noviembre de 2024, antes de la apertura del mercado. La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo de audio a las 10:00 AM ET el mismo día. La transmisión estará accesible a través del sitio web de Relaciones con Inversores de UroGen, con una repetición disponible durante aproximadamente 30 días después.
UroGen Pharma (Nasdaq: URGN), 비뇨 암 및 전문 암 치료에 중점을 둔 생명공학 회사가 2024년 3분기 재무 결과를 2024년 11월 6일 수요일, 시장 개장 전에 발표할 예정입니다. 회사는 같은 날 오전 10시(동부 표준시)에 컨퍼런스 콜 및 실시간 오디오 웹캐스트를 개최합니다. 웹캐스트는 UroGen의 투자자 관계 웹사이트를 통해 접근 가능하며, 약 30일 동안 다시 볼 수 있습니다.
UroGen Pharma (Nasdaq: URGN), une entreprise de biotechnologie axée sur les traitements du cancer urotéhelial et spécialisé, publiera ses résultats financiers du troisième trimestre 2024 le mercredi 6 novembre 2024, avant l'ouverture des marchés. L'entreprise tiendra une conférence téléphonique et un webinaire audio en direct à 10h00 HE le même jour. Le webinaire sera accessible via le site Web des relations avec les investisseurs d'UroGen, avec une rediffusion disponible pendant environ 30 jours après.
UroGen Pharma (Nasdaq: URGN), ein Biotech-Unternehmen, das sich auf uroteliale und spezialisierte Krebstherapien konzentriert, wird seine Finanzresultate für das dritte Quartal 2024 am Mittwoch, dem 6. November 2024, vor Handelsbeginn veröffentlichen. Das Unternehmen wird am selben Tag um 10:00 Uhr ET eine Telefonkonferenz und einen Live-Audio-Webcast veranstalten. Der Webcast wird über die Investor-Relations-Website von UroGen zugänglich sein, mit einer Wiederholung, die etwa 30 Tage lang verfügbar ist.
- None.
- None.
Conference Call and Webcast Scheduled for Wednesday, November 6, 2024, at 10:00AM ET
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030832940/en/
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: UroGen Pharma Ltd.
FAQ
When will UroGen Pharma (URGN) report Q3 2024 earnings?
What time is UroGen Pharma's (URGN) Q3 2024 earnings call?
How can I access UroGen Pharma's (URGN) Q3 2024 earnings call?
